FDA commissioner
This article was originally published in The Rose Sheet
Executive Summary
Acting chief Andrew von Eschenbach, MD, is nominated by President Bush to head the agency permanently March 15. Von Eschenbach assumed the acting role last fall following the resignation of FDA Commissioner Lester Crawford (1"The Rose Sheet" Oct. 3, 2005, p. 6). Road to confirmation may be a rocky one, however: Sens. Hillary Clinton (D-N.Y.) and Patty Murray (D-Wash.) threatened to place a hold on nomination until FDA issues a decision on over-the-counter switch application for Barr's Plan B emergency contraceptive...
You may also be interested in...
FDA Head Von Eschenbach Resigning In January; Industry Awaits Successor
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, closing out a bumpy tenure marked by some notable successes
Senators Seek To Clear Hurdles On Von Eschenbach Nomination
Senate Health committee members are working to break the Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post
FDA Morale Improvement Will Be A Priority, Von Eschenbach Testifies
Acting Commissioner Andrew von Eschenbach stressed his commitment to improving agency morale during his confirmation hearing